Dennis Walsh Biography and Net Worth

Director of Deciphera Pharmaceuticals

Mr. Walsh has served as a member of the Board of Directors of Deciphera Pharmaceuticals since February 2015. He has over 30 years of experience in the financial services industry. Mr. Walsh is currently Senior Vice President and Chief Financial Officer of Americo Life, Inc., a privately owned life insurance company, a role he has held since October 2018. Prior to Americo, Mr. Walsh was a partner with Walsh Washburn, LLC, a tax and finance consulting firm, which he co-founded in 2003. Mr. Walsh began the first ten years of his career with Deloitte. Mr. Walsh currently serves on the Board of Directors of several Americo affiliates. He received a Masters degree in Accounting from the University of Missouri, Kansas City as well as a B.S. B.A. in Accounting from Rockhurst University and is a Certified Public Accountant.

What is Dennis Leo Walsh's net worth?: The estimated net worth of Dennis Leo Walsh is at least $281.49 thousand as of May 10th, 2023. Mr. Walsh owns 11,000 shares of Deciphera Pharmaceuticals stock worth more than $281,490 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Walsh may own. Learn More about Dennis Leo Walsh's net worth.
How do I contact Dennis Leo Walsh?: The corporate mailing address for Mr. Walsh and other Deciphera Pharmaceuticals executives is 200 SMITH STREET, Waltham MA, 02451. Deciphera Pharmaceuticals can also be reached via phone at (781) 209-6400 and via email at [email protected]. Learn More on Dennis Leo Walsh's contact information.
Has Dennis Leo Walsh been buying or selling shares of Deciphera Pharmaceuticals?: Dennis Leo Walsh has not been actively trading shares of Deciphera Pharmaceuticals during the last quarter. Most recently, on Wednesday, May 10th, Dennis Leo Walsh bought 11,000 shares of Deciphera Pharmaceuticals stock. The stock was acquired at an average cost of $13.86 per share, with a total value of $152,460.00. Following the completion of the transaction, the director now directly owns 11,000 shares of the company's stock, valued at $152,460. Learn More on Dennis Leo Walsh's trading history.
Who are Deciphera Pharmaceuticals' active insiders?: Deciphera Pharmaceuticals' insider roster includes James Bristol (Director), Daniel Flynn (Insider), Franklin Friedman (Director), Steven Hoerter (CEO), Thomas Kelly (CFO), Matthew Sherman (EVP), Michael Taylor (Director), and Dennis Walsh (Director). Learn More on Deciphera Pharmaceuticals' active insiders.

Dennis Leo Walsh Insider Trading History at Deciphera Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/10/2023	Buy	11,000	$13.86	$152,460.00	11,000

Dennis Leo Walsh Buying and Selling Activity at Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $25.59

$25.59

50 Day Range

MA: $25.59

$25.55

$25.59

2 Week Range

Now: $25.59

$9.90

$25.61

Volume

600 shs

Average Volume

1,292,551 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield